Management of Rare Histological Types of Breast Tumours.
Breast tumours exhibit a wide range of morphological phenotypes, and specific histopathological types have particular prognostic and clinical characteristics. The management of uncommon premalignant and malignant lesions is often controversial due to the lack of large single-institution studies or randomised trials to define optimal treatments. In the era of frequent use of treatment guidelines, only a low level of evidence exists for the management of rare histological types of breast tumours. This review is divided into two parts: Firstly, the favourable histological subtypes like tubular, mucinous, medullary breast cancers, and phyllodes tumour (benign, borderline, and malignant) are discussed. The prognosis of these selected lesions is believed to be better than for invasive ductal carcinoma so that in some cases even less aggressive treatment should be considered. Patients with these specific histological types should be informed of this relatively favourable prognosis. Secondly, management recommendations for special situations like Paget's disease (tumour of the nipple) and inflammatory breast carcinoma are presented.
Reimer
Toralf
T
Department of Obstetrics and Gynaecology, University of Rostock, Klinikum Suedstadt, Germany.
Breast Cancer Res. 1999;1(1):31-5
11250680
Breast Cancer Res Treat. 2008 Dec;112(3):513-21
18240020
Ann Surg Oncol. 2007 Mar;14(3):1020-3
17195914
Arch Gynecol Obstet. 2008 Feb;277(2):135-8
17701193
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75
15998949
J Clin Oncol. 2008 Mar 1;26(7):1066-72
18212337
Arch Gynecol Obstet. 2004 May;269(4):278-81
15205980
Cancer. 1977 Oct;40(4):1365-85
907958
Cancer. 1996 Feb 15;77(4):697-709
8616762
Cancer Treat Rev. 1988 Mar;15(1):53-63
3282651
Breast Cancer Res Treat. 2007 Apr;102(2):137-42
17028984
Cancer. 2007 Oct 1;110(7):1436-44
17694554
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1149-54
16750330
Arch Gynecol Obstet. 2007 Dec;276(6):649-53
17549503
Am J Surg. 2002 Dec;184(6):492-8; discussion 498
12488144
Clin Radiol. 2006 May;61(5):423-30
16679116
Ann Oncol. 2007 Jun;18(6):1021-9
17351259
Am J Clin Pathol. 2006 Jul;126(1):55-8
16753605
Cancer. 2000 Oct 1;89(7):1502-11
11013364
J Clin Oncol. 2003 Jun 15;21(12):2254-9
12805323
Semin Diagn Pathol. 2004 Feb;21(1):65-73
15074561
J Surg Oncol. 1995 Mar;58(3):162-7
7898111
Cancer. 2006 Nov 1;107(9):2127-33
16998937
Curr Treat Options Oncol. 2004 Apr;5(2):153-60
14990209
Cancer. 1989 Jun 15;63(12):2532-6
2541890
Ann Surg Oncol. 2005 Jan;12(1):24-8
15827774
Breast Cancer Res Treat. 1990 Oct;16(3):215-29
2085673
Cancer. 1988 Mar 1;61(5):989-96
2827884
Acad Radiol. 2008 Feb;15(2):209-21
18206620
Cancer Treat Rev. 2001 Feb;27(1):9-18
11237774
Breast Cancer Res Treat. 2008 Jun;109(3):417-26
17653852
Am J Surg. 2007 Oct;194(4):527-31
17826073
Ann Surg Oncol. 2007 Oct;14(10):2961-70
17562113
Radiographics. 2003 Jul-Aug;23(4):881-95
12853663
Ann Surg Oncol. 2005 May;12(5):391-7
15915373
Breast Cancer Res Treat. 2005 Oct;93(3):199-205
16142444
J Clin Oncol. 1999 Nov;17(11):3653-63
10550164
J Clin Oncol. 1999 May;17(5):1442-8
10334529
Breast Cancer Res Treat. 2008 Sep;111(2):313-9
17952590
J Clin Pathol. 2008 Jan;61(1):11-9
17873114
Cancer. 1999 Apr 1;85(7):1530-6
10193943
Breast Cancer Res Treat. 2008 Oct;111(3):541-7
18026874
Breast Cancer. 2000 Jan;7(1):65-70
11029773
Br J Cancer. 2007 Oct 8;97(7):883-7
17876327
Int J Cancer. 2007 Jul 1;121(1):127-35
17330844
Eur J Radiol. 2007 Jan;61(1):158-62
16987629
Eur J Radiol. 2000 Jul;35(1):39-43
10930764
Arch Surg. 1999 May;134(5):487-92; discussion 492-3
10323420
J Clin Oncol. 2008 Feb 10;26(5):786-90
18258987
Cancer. 2007 Nov 1;110(9):1929-36
17896781